Alligator publishes supplementary prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Notice of annual general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 24 April 2023, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows ...
Alligator Bioscience AB: Interim report January–March 2022
A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key ass ...
Notice of annual general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Issue and repurchase of series C shares for performance-based share saving program
Pursuant to the authorization granted by the annual general meeting on 1 June 2021, the board of directors of Alligator Bioscience AB (”Alli ...
The Nomination Committee’s proposal regarding the Board of Directors ahead of the Annual General Meeting 2022 in Alligator Bioscience AB
REGULATORY 11 March 2022 Ahead of the Annual General Meeting in Alligator Bioscience AB on May 5, 2022, the Nomination Committee announces i ...
Alligator Bioscience AB: Interim report January–September 2021
First Patient Dosed in Optimize-1 Phase II “We continued to make great strides in the third quarter of 2021. The first patient was dosed in ...